ARR-217 + bevacizumab

ARR-217 + bevacizumab is an investigational combination regimen consisting of ARR-217 (also known as MRG007), a cadherin-17 (CDH17)-targeted antibody-drug conjugate (ADC), and bevacizumab, a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF). ARR-217 consists of a humanized anti-CDH17 monoclonal antibody conjugated to a glycan-linked, exatecan-based topoisomerase I inhibitor payload with a drug-to-antibody ratio (DAR) of 4. Bevacizumab acts as an angiogenesis inhibitor by binding to VEGF and preventing its interaction with VEGF receptors. The combination is being developed by ArriVent BioPharma (which holds exclusive rights outside Greater China) and Lepu Biopharma (the originator of MRG007). The regimen is currently being evaluated in a Phase 1/1b clinical trial (NCT07066657) for the treatment of unresectable locally advanced or metastatic solid tumors, with a primary focus on late-line colorectal cancer, as well as other gastrointestinal malignancies such as gastric and pancreatic cancers.